Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [12725]

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

Researchers find evidence that diet can alter the microbiome to affect breast cancer risk

Researchers find evidence that diet can alter the microbiome to affect breast cancer risk

European Commission approves nivolumab plus ipilimumab as first-line treatment for mesothelioma

European Commission approves nivolumab plus ipilimumab as first-line treatment for mesothelioma

Novel antibody drug wakes up the body's defence system in advanced-stage cancer

Novel antibody drug wakes up the body's defence system in advanced-stage cancer

Ageing impairs anti-tumour T-cell response via mitochondria dysfunction

Ageing impairs anti-tumour T-cell response via mitochondria dysfunction

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk and poor-risk clear cell RCC

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk and poor-risk...

Analysing tumour microenvironment at single cell level sheds light on metastatic melanoma outcomes

Analysing tumour microenvironment at single cell level sheds light on metastatic melanoma outcomes

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line immunotherapy in advanced bladder cancer

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line...

ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk early-stage HER2...

More from ecancer